万赛维治疗CMV视网膜炎的疗效怎么样？

The tablet is an oral anti-cytomegalovirus infection drug developed by the Swiss company Roche. The main ingredient is valganciclovir hydrochloride. Vansevir tablets are the L-valyl ester (prodrug) of ganciclovir. After oral administration, Vansevir tablets are rapidly converted into ganciclovir by esterases in the small intestine and liver. Vancevir is a synthetic 2’-deoxyguanosine monophosphate analogue that inhibits herpes virus replication in vitro and in vivo.

Human viruses to which Vancevir is sensitive include human cytomegalovirus (HCMV), Vancevir is sensitive to herpes simplex virus-1 and herpes simplex virus-2 (HSV-1, HSV-2), human herpesvirus-6, 7, 8 (HHV-6, 7, 8), Epstein-Barr virus, varicella-zoster virus (VZV) and hepatitis B virus. In cells infected by cytomegalovirus (CMV), Vancevir tablets are first phosphorylated by the viral protein kinase UL97 into ganciclovir monophosphate, and then further phosphorylated by intracellular protein kinases into ganciclovir triphosphate, and then slowly metabolized within the cell.

Clinically, Vancevi tablets are mainly used to treat patients with acquired immunodeficiency syndrome (AIDS) combined with cytomegalovirus (CMV) retinitis. What about Vancevi tablets?

Clinical studies of Vancevir tablets in AIDS patients infected with CMV retinitis have shown that Vancevir tablets and intravenous ganciclovir are equally effective in the induction treatment of CMV retinitis. In the study, patients with newly diagnosed CMV retinitis were randomly assigned to the Vancevir tablet group or the intravenous ganciclovir group for induction therapy. The proportion of patients with progression of CMV retinitis at week 4 was the same in both groups. After induction therapy, both groups of patients in the study continued to receive maintenance therapy at 900 mg tablets per day. Among patients who received induction therapy with Vancevir tablets or intravenous ganciclovir tablets followed by maintenance therapy with valganciclovir hydrochloride tablets, the mean (median) time from randomization to progression of CMV retinitis was: 226 (160) days and 219 (125) days.